<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:30</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:30-09:55</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>09:55-10:00</td>
<td><strong>Keynote Forum</strong></td>
</tr>
<tr>
<td>Introduction</td>
<td></td>
</tr>
</tbody>
</table>
| 10:00-10:40| Title: A small peptide derived from a neuronal cell cycle like kinase activator, P35, is a possible therapeutic candidate to reduce the phenotypes of neurodegenerative disorders  
Harish C Pant, NINDS-NIH, USA |
| Refreshments 10:40-11:00 |                                                                                          |
| 11:00-11:40| Title: Degeneration of the Thalamostriatal System: A Potential Source of Early Cognitive Impairments in Parkinson's Disease  
Yoland Smith, Emory University, USA |
| Group Photo & Panel Discussion |                                                                                          |
| 11:40-12:20| **Workshop**                                                                               |
| Title: St. Jude Medical |                                                                                          |
| Jeff Kramer, St. Jude Medical, USA |                                                                                          |
| Sessions: Parkinsons: Pathophysiology and Neuropharmacology | Neuromuscular and Neurocognitive Disorders |
| Session Chair: Yoland Smith, Emory University, USA |                                                                                          |
| 12:20-12:50| Title: Preventing Parkinson's  
Bennett Weinstock, Weinstock Physical Therapy, PC, USA |
| 12:50-13:20| Title: Articulatory Kinematics and speech dysfunction in patients with Parkinson's disease  
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA |
| Lunch Break 13:20-14:10 |                                                                                          |
| 14:10-14:40| Title: Clinical Trials using MRI Guided Focused Ultrasound (ExAblate Transcranial System) for the management of Medically-Refractory Dyskinesia Symptoms of advanced Idiopathic Parkinson's Disease and in patients with Benign Essential Tremors  
Charlene Aldrich, University of Maryland School of Medicine, USA |
| 14:40-15:10| Title: Parkinson's Disease is not a Disease  
Rudy Capildeo, Nuffield Hospital, UK |
| 15:10-15:40| Title: What makes a parkinson patient fall  
Bhanu Kesavamurthy, Madras Medical College, India |
| Refreshments 15:40-16:00 |                                                                                          |
| 16:00-16:40| Title: Impact of Sirtine 3 in cognotove deficits in Parkinson’s disease  
Jie Wu, Barrow Neurological Institute, USA |
| Panel Discussion |                                                                                          |
| 09:00-09:30| Registrations                                                                           |
| 09:30-09:55| Opening Ceremony                                                                         |
| 09:55-10:00| **Keynote Forum**                                                                         |
| 10:00-10:40| Title: Parkinson's: The First Consultation – My Approach  
Rudy Capildeo, Nuffield Hospital, UK |
| Refreshments 10:50-11:10 |                                                                                          |
| 11:00-11:40| Title: Clinical Conundrum of Neuroleptic Malignant Syndrome - A New Look and a New AVS-CUV Criterion  
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA |
| Sessions: Diagnosis of Parkinsons | Risk factors in Parkinsons | Mananging Life in Parkinsons Disease |
| Session Chair: Rudy Capildeo, Nuffield Hospital, UK |                                                                                          |
| 11:00-11:40| Title: Clinical Conundrum of Neuroleptic Malignant Syndrome - A New Look and a New AVS-CUV Criterion  
Srinivas Avathvadi Venkatesan, Hershe Medical College, USA |
| 11:40-12:20| Title: Nesfatin-1 protects dopaminergic neurons against MPTP neurotoxicity through C-Raf/ERK1/2 dependent anti-apo  
Hong Jiang, Qingdao University, China |
| 12:00-12:50| Title: Exercise prescriptions for Parkinson diseases  
Bennett Weinstock, Weinstock Physical Therapy, USA |
| 12:20-12:50| Title: Exercise prescriptions for Parkinson diseases  
Bennett Weinstock, Weinstock Physical Therapy, USA |
Title: Disrupted-in-schizophrenia 1 (DISC1) L100P mutation alters synaptic transmission and plasticity in the hippocampus and causes recognition memory deficits
Yu Zhou, Qingdao University, China

Lunch Break 13:20-14:10

14:10-14:40
Title: Dystonia profile in a tertiary care hospital from southern India
Prabaharan Chellamuthu, Madras Medical College, India
Title: Inhibition of high mobility group box 1 (HMGB1) as a neuroprotective treatment in the MPTP mouse model of Parkinson’s disease.
Matteo Santoro, University of Aberdeen, UK
Title: Effect of Delayed Post-Treatment With Adult-Sourced Adipose-Derived Mesenchymal Stem Cells on Motor Function and Striatal Medium-Spiny Projection Neurons After Neonatal Rat Hypoxia-Ischemia
Benjamin E. Aghoghovvvia, University of Otago, New Zealand

Panel Discussion

Refreshments 16:10-16:30

Day 3  December 07, 2016
Conference Hall

Sessions:
Novel Insights and Therapeutic Approach in Parkinsons
Session Chair: Srinivas Avathvadi Venkatesan, Hershe Medical College, USA

10:00-10:30
Title: Dopamine D1 and D2 receptor subtypes functional regulation in unilateral rotenone lesioned Parkinson’s rat model: Effect of serotonin, dopamine and norepinephrine
Jes Paul, American University of St vincent, Saint Vincent and the Grenadines

Refreshments 10:30-10:50

Workshop
10:50-11:50
Title: TREQUANT- Tremor quantifying wearable for movement disorder patients
Usman Shabbix, Comsats Institutes of Information Technology, Pakistan

Panel Discussion
Poster Presentations @ 11:50-13:30

PD1
Title: Activation of NLRP3-inflammasome in the MPTP mouse model of Parkinson’s disease might be triggered by HMGB1-MAC-1 axis
Matteo Santoro, University of Aberdeen, UK

PD2
Title: Grape skin powder mediates mitochondria function by autophagy activation and exhibits potential protective benefit in a Drosophila Parkinson’s Disease Model
Alan Wu, Stanford University, USA

PD3
Title: Disorder of action preparation in schizophrenia
Denisas Dankinas, Vilnius University, Lithuania

PD4
Title: Role of Therapeutic Touch in the management of responsive behavior in patients with dementia
Helen Senderovich, University of Toronto, Canada

PD5
Title: Next Generation Sequencing data analysis evaluation in patients with Parkinsonism from genetically isolated population
Radek Vodicka, Palacky University, Czech Republic

PD6
Title: Differences in vulnerability of neurons and astrocytes to heme oxygenase-1 modulation: Implications for mitochondrial ferritin
Junxia Xie, Qingdao University, China

PD7
Title: Bioinorganic Implications and Strategies in Parkinson’s Disease
Heather R. Lucas, Virginia Commonwealth University, USA

PD8
Title: Acceleration of de novo early bone defect healing following application of s-nitroso glutathione in vivo
Xin wang, Queensland University of Technology, Australia

PD9
Title: Dystonia profile in a tertiary care hospital from southern india
Prabaharan Chellamuthu, Madras Medical College, India

Lunch Break: 13:30-14:15

14:15-14:45
Title: Holistics support services for individual’s with movement disorders
Steven Sydowski, University of Scranton, USA

Panel Discussion 15:15-15:45

14:45-15:15
Title: Integration of Palliative Care in the management of Parkinson’s disease
Helen Senderovich, University of Toronto, Canada

Networking and B2B Meeting@16:05-17:00

Award & Closing Ceremony
Scientific Program

International Conference on
Parkinson's Disease & Movement Disorders
August 11-13, 2015   Frankfurt, Germany
### Scientific Program

#### Day 1  
August 11, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:30</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:30-09:55</td>
<td><strong>Opening Ceremony</strong></td>
</tr>
<tr>
<td>09:55-10:00</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 10:00-10:40 | **Kjell Fuxe**  
  Karolinska Institutet, Sweden                                          |
| 10:40-11:20 | **Michael Ugrumov**  
  Institute of Developmental Biology RAS, Russia                         |
| 11:40-12:10 | Movement disorder and neurodegeneration in a rat model with myosin 5a mutation  
  **George Stoica**, Texas A&M University, USA                            |
| 12:10-12:40 | Mutation analysis of CHCHD10 in neurodegenerative diseases, including Parkinson’s disease  
  **Ekaterina Rogaeva**, University of Toronto, Canada                    |
| 12:40-13:10 | Analysis of volatile organic compounds in rats with dopaminergic lesion: Possible application for early detection of Parkinson’s disease  
  **Soliman Khatib**, MIGAL–Galilee Research Institute, Israel           |
| 14:00-14:30 | The concentration of oxidized DJ-1 protein (oxDJ-1) in red blood cells is useful for the diagnosis method of Parkinson’s disease  
  **Kazumasa Saigoh**, Kinki University, Japan                            |
| 16:30-17:00 | Prevalence of Parkinson’s disease in Egypt: A review of community-based survey  
  **Eman Khedr**, Assiut University, Egypt                                |
| 17:00-17:30 | The effect of systemic inflammation induced by a high sucrose diet, on inflammation in the rat substantia nigra  
  **Ashton Rogers**, University of the West Indies, West Indies            |

### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:55-10:00</td>
<td><strong>Introduction</strong></td>
</tr>
</tbody>
</table>
| 10:00-10:40 | **Kjell Fuxe**  
  Karolinska Institutet, Sweden                                          |
| 10:40-11:20 | **Michael Ugrumov**  
  Institute of Developmental Biology RAS, Russia                         |

### Session on: Associate Disorders like Neurocognitive and Degenerative Disorder

**Session Chair: Ekaterina Rogaeva**, University of Toronto, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 11:40-12:10 | Movement disorder and neurodegeneration in a rat model with myosin 5a mutation  
  **George Stoica**, Texas A&M University, USA                            |
| 12:10-12:40 | Mutation analysis of CHCHD10 in neurodegenerative diseases, including Parkinson’s disease  
  **Ekaterina Rogaeva**, University of Toronto, Canada                    |
| 12:40-13:10 | Analysis of volatile organic compounds in rats with dopaminergic lesion: Possible application for early detection of Parkinson’s disease  
  **Soliman Khatib**, MIGAL–Galilee Research Institute, Israel           |

### Lunch Break 13:10-14:00 @ Restaurant

- **Kazumasa Saigoh**, Kinki University, Japan

### Session Discussion

#### Workshop on: On the role of A1-D1 heteroreceptor complexes in the direct pathway in models of Parkinson’s disease

**Dasiel O Borroto Escuela**, Karolinska Institutet, Sweden

### Session on: Basic Science and Epidemiology

**Session Chair: Michael Ugrumov**, Institute of Developmental Biology RAS, Russia

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16:30-17:00 | Prevalence of Parkinson’s disease in Egypt: A review of community-based survey  
  **Eman Khedr**, Assiut University, Egypt                                |
| 17:00-17:30 | The effect of systemic inflammation induced by a high sucrose diet, on inflammation in the rat substantia nigra  
  **Ashton Rogers**, University of the West Indies, West Indies            |

### Coffee Break 16:00-16:30 @ Foyer
### Raume / Room - 4
**Day 2 August 12, 2015**

#### Keynote Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-10:40</td>
<td>Robert W Ledeen</td>
<td>New Jersey Medical School, USA</td>
</tr>
<tr>
<td>10:40-11:20</td>
<td>George Stoica</td>
<td>Texas A&amp;M University, USA</td>
</tr>
</tbody>
</table>

**Coffee Break 11:20-11:40 @ Foyer**

**Session on: Novel Insights and Therapeutics for Parkinson’s Disease**
**Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:40-12:10</td>
<td>Neuroplasticity in the Nigrostriatal system of MPTP-treated mice at presymptomatic and early symptomatic stages of parkinsonism</td>
<td>Michael Ugrumov, RAS Center for Brain Research, Russia</td>
</tr>
<tr>
<td>12:10-12:40</td>
<td>Use of human embryonic stem cells in the treatment of Parkinson’s disease</td>
<td>Geeta Sharoff, Nutech Mediworld, India</td>
</tr>
</tbody>
</table>

**Lunch Break 12:40-13:30 @ Restaurant**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:00</td>
<td>Evaluation of a rhythmic exercise program for patients with Parkinson’s disease</td>
<td>Audun Myskja, Norwegian Parkinson Org, Norway</td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Dyskinesia associated with old and new therapies in Parkinson’s disease</td>
<td>Sanjay Jaiswal, Jaiswal Hospital and Neuro Institute, India</td>
</tr>
<tr>
<td>14:30-15:30</td>
<td>Workshop on The impact of DA heteroreceptor complexes and their receptor-receptor interactions in Parkinson’s disease and its treatment by Kjell Fuxe, Karolinska Institutet, Sweden</td>
<td>Kjell Fuxe, Karolinska Institutet, Sweden</td>
</tr>
</tbody>
</table>

#### Young Researcher Forum

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:30</td>
<td>The effects of increased therapy time on cognition and mood in frail patients with a stroke who rehabilitate on rehabilitation units of nursing homes in the Netherlands</td>
<td>Marleen Huijben, University of Amsterdam, Netherlands</td>
</tr>
<tr>
<td>16:30-17:00</td>
<td>Hyperkinetic movement disorders, differential diagnosis and treatment</td>
<td>Arunasalam Balamanogaran, Gomel State Medical University, Belarus</td>
</tr>
</tbody>
</table>

#### Poster Presentations @ 17:00-17:45

<table>
<thead>
<tr>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>Curcumin’s neuroprotective efficacy in drosophila model of idiopathic Parkinson’s disease is phase specific Implicatin of its therapeutic effectiveness</td>
<td>Limamanen Phom, Nagaland University, India</td>
</tr>
<tr>
<td>Protective effects of rosmarinic acid against iron-induced neurotoxicity in SK-N-SH cells</td>
<td>Huamin Xu, Qingdao University, China</td>
</tr>
<tr>
<td>Mice expressing the A53T mutant form of human alpha-synuclein exhibit unexpected improvements of spatial learning and memory abilities</td>
<td>Ze Gang Ma, Qingdao University, China</td>
</tr>
<tr>
<td>Bidirectional modulation by HCN channels on globus pallidus neurons</td>
<td>Lei Chen, Qingdao University, China</td>
</tr>
<tr>
<td>GPER agonist G1 attenuates LPS-induced inflammatory responses in murine BV-2 microglial cells</td>
<td>Wen-fang Chen, Qingdao University, China</td>
</tr>
<tr>
<td>Sulforaphane ameliorates 3-nitropropionic acid-induced striatal toxicity by activating the Keap1-Nrf2-ARE pathway and inhibiting the MAPKs and NF-kB pathways</td>
<td>Ik-Hyun Cho, Kyung Hee University, Republic of Korea</td>
</tr>
<tr>
<td>Protective effects and mechanisms of rosmarinic acid against rotenone-induced Parkinson’s disease models</td>
<td>Jun-xia Xie, Qingdao University, China</td>
</tr>
<tr>
<td>NR2B Antagonist ifenprodil improves abnormal forelimb movement induced by D1R agonist SKF38393 in hemikerkinsonian rats</td>
<td>Toshiya Habata, Kitasato University, Japan</td>
</tr>
</tbody>
</table>
| PDMD-009 | Treatment of dystonia and tremors in Parkinson's disease  
| Sanjay Jaiswal, Jaiswal Hospital and Neuro Institute, India |
| PDMD-010 | Characterizing the mode of action of beta-2 adrenergic receptor agonists: A therapeutic agent for Parkinson's disease  
| Naik Bakht Arbazada, University of Alberta, Canada |

**Raume / Room - 4**

Session on: Novel Insights and Therapeutics for Parkinson’s Disease  
**Session Chair: Kjell Fuxe, Karolinska Institutet, Sweden**

| Time | Session Introduction  
| 10:00-10:30 | Thioredoxin-1 suppresses MPP+/MPTP neurotoxicity through enhancing autophagy  
| Bai Jie, Kunming University of Science and Technology, China |
| 10:30-11:00 | On the role of A1-D1 heteroreceptor complexes in the direct pathway in models of Parkinson’s disease  
| Daniel O Borroto Escuela, Karolinska Institutet, Sweden |

**Coffee Break 11:00-11:30 @ Foyer**

| Time | Session Introduction  
| 11:30-12:00 | The impact of DA heteroreceptor complexes and their receptor-receptor interactions in Parkinson’s disease and its treatment  
| Kjell Fuxe, Karolinska Institutet, Sweden |
| 12:00-12:30 | New gene therapy approaches for Parkinson’s disease  
| Jose Lanciego, Center for Applied Medical Research (CIMA and CIBERNED), Spain |

**Lunch Break 12:30-13:30 @ Restaurant**

**Award Ceremony**

---

**Bookmark your dates**

**2nd International Conference on**

**Parkinson's Disease & Movement Disorders**

**December 08-10, 2016  Philadelphia, USA**

**Website:** [http://parkinsons.conferenceseries.com](http://parkinsons.conferenceseries.com)